Related Experiment Video

Updated: Dec 17, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.5K

Relationship between interleukin-13 rs20541 single nucleotide polymorphisms and therapeutic efficacy in children with

Lixiao Liu1, Dongmei Yue2, Lan Hu3

  • 1Shanghai Pudong Hospital, Shanghai, China.

The Journal of International Medical Research
|June 27, 2020
PubMed

Insights

Children with asthma carrying the GG allele for interleukin-13 (IL-13) rs20541 polymorphism showed better response to budesonide and fluticasone treatment. This asthma treatment is effective, with GG allele carriers experiencing faster symptom relief and improved lung function.

Area of Science:

  • Genetics and Immunology
  • Pediatric Pulmonology

Background:

  • Asthma management in children requires effective treatment strategies.
  • Interleukin-13 (IL-13) gene polymorphisms may influence treatment response.

Purpose of the Study:

  • To examine the association between IL-13 rs20541 polymorphisms and therapeutic efficacy in pediatric asthma.
  • To evaluate the impact of specific IL-13 genotypes on treatment outcomes for moderate-to-severe asthma.

Main Methods:

  • Fifty children with moderate-to-severe asthma were genotyped for IL-13 rs20541 polymorphism (GG, GA, AA).
  • Patients received budesonide inhalation suspension and fluticasone propionate.
  • Clinical symptoms, lung function (FEV1, PEF), and adverse reactions were monitored.

Main Results:

  • No significant pre-treatment lung function differences were observed among genotype groups.
  • The GG genotype group demonstrated significantly shorter symptom relief times post-treatment.
  • Improved forced expiratory volume in one second (FEV1) and percent predicted peak expiratory flow (PEF) were noted in the GG group.

Conclusions:

  • Budesonide and fluticasone combination therapy is effective for moderate-to-severe pediatric asthma.
  • IL-13 rs20541 polymorphism correlates with therapeutic efficacy.
  • GG allele carriers exhibit enhanced responsiveness to the studied asthma treatment regimen.
Abstract

Keywords:
Interleukin-13bronchial asthmabudesonidefluticasonegene polymorphisminhaled glucocorticoidlong-acting β2-adrenoceptor agonisttherapeutic efficacy

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

669
An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

7.8K

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.6K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.9K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K